Harrow focuses on ophthalmology products, including Iheezo, Vevye, and Triesence, but its clinical differentiation is debatable. HROW reported a record $48.9 million in Q2 revenue, a 46% year-over ...

Harrow's acquisition and relaunch of Triesence, with 39,000 units available, positions the company for significant market growth, targeting over 500,000 units annually.

In the world of agriculture, the harrow is a vital tool for soil preparation, breaking up clumps of earth, and ensuring optimal seedbed conditions. But not all harrows are created equal. In this ...

NASHVILLE, Tenn., March 24, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has ...

NASHVILLE, Tenn., May 05, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first quarter ...